Home/Pipeline/Not Specified (Solid Tumors)

Not Specified (Solid Tumors)

Solid Tumors

ClinicalActive

Key Facts

Indication

Solid Tumors

Phase

Clinical

Status

Active

Company

AbelZeta Pharma

About AbelZeta Pharma

AbelZeta Pharma is a clinical-stage biotechnology company pioneering T cell-based therapies for hematologic malignancies, solid tumors, and inflammatory/immunological diseases. The company leverages a proprietary CAR-T platform and is led by a management team with deep experience from major technology and pharmaceutical corporations. While currently a private, pre-revenue entity, it is advancing a pipeline of novel cell therapies with the aim of providing personalized treatments for challenging conditions.

View full company profile

Therapeutic Areas

Hematologic Malignancies Inflammatory & Immunological Diseases Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed